Compare TTWO & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | TNDM |
|---|---|---|
| Founded | 1993 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.2B | 1.5B |
| IPO Year | 1997 | 2013 |
| Metric | TTWO | TNDM |
|---|---|---|
| Price | $241.87 | $21.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 20 | 16 |
| Target Price | ★ $269.25 | $22.44 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,219,900,000.00 | $1,007,001,000.00 |
| Revenue This Year | $17.42 | $8.59 |
| Revenue Next Year | $38.29 | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 13.98 | ★ 17.87 |
| 52 Week Low | $177.35 | $9.98 |
| 52 Week High | $264.79 | $38.28 |
| Indicator | TTWO | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 64.60 |
| Support Level | $245.99 | $20.27 |
| Resistance Level | $250.18 | $22.10 |
| Average True Range (ATR) | 4.16 | 1.13 |
| MACD | 0.27 | -0.10 |
| Stochastic Oscillator | 41.34 | 80.51 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.